USA |NYSE MKT |USD
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
|Public Float||18.45M||P/E Ratio||-|
|% Short of Float||-||Dividend (Yield)||-|
|Held by Insiders||43.47%||Ex-Dividend Date|
|Held by Institutions||17.94%||IPO Date||Nov 29, 2018|
|Dec 21||Dec 20||Dec 19|
|Mar 22||Dec 21||Sep 21|
|Jun 15, 2022||$0.64||$0.74||$0.64||$0.68||3.27%||35.11K|
|Jun 22, 2022||$0.60||$0.66||$0.60||$0.66||14.67%||9.56K|
|Jun 24, 2022||$0.60||$0.64||$0.57||$0.57||-21.48%||51.87K|
Last quarter (ended on March 31 ,2022) Agex therapeutics generated a net income of $-2.71M, representing a 22.84% decrease compared to the same quarter a year before (ended on March 31 ,2021).
Last fiscal year (ended on December 31 ,2021) Agex therapeutics generated a net income of $-8.68M, representing a 20.96% decrease compare to the previous fiscal year (ended on December 31 ,2020).
View More Details on Agex therapeutics's “Financials” Section
Agex therapeutics is expected to report earnings on August 10 ,2022.
View More Details on Agex therapeutics's 'Earnings' Section
Agex therapeutics trades on the NYSE American stock market in USA under the ticker symbol "AGE". Agex therapeutics’s stock symbol can also be displayed as "NYSEAMERICAN:AGE".
Agex therapeutics (NYSEAMERICAN:AGE) is owned by 17.94% institutional shareholders and by 43.47% insiders. The rest is owned by the public.
Explore More Details on Agex therapeutics's “Ownership” Section
Agex therapeutics's key executive team includes the following managers:
Agex therapeutics (NYSEAMERICAN:AGE) is classified under the "Healthcare" sector and under the "Biotechnology" industry.
Currently the number of employees working for Agex therapeutics is 5.
Agex therapeutics (NYSEAMERICAN:AGE) is headquartered in CA, United States.
Agex therapeutics’s mailing address is 1101 Marina Village Parkway, Alameda, CA, United States, 94501.
The company’s phone number is 510 671 8370.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.